FDA Clears AccelSPINE's Next Generation Minimally Invasive Spine System

Written by Anuja Vaidya | May 05, 2014 | Print  |

AccelSPINE has received U.S. Food and Drug Administration clearance on its Picasso II system.

Picasso II is intended to immobilize and stabilize spinal segments as a supplement to fusion during the treatment of acute and chronic instabilities or deformities of the spine. It is an addition to the company's Picasso product line.


AccelSPINE is a national medical device company that designs, develops and manufactures spinal implants and instruments.

More Articles on Devices:

Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers